Veranex recently introduced the medical technology industry's first Innovation CRO (iCRO). This innovation represents a transformative approach to medical device and diagnostic development as it addresses critical challenges in today's constrained funding environment.
Veranex's integrated service model combines traditional contract research organization capabilities with comprehensive product development expertise across the entire lifecycle — from initial concept through regulatory approval and market access. The iCRO framework operates through four foundational elements, including accelerated development timelines promising three to six month reductions per phase, evidence generation strategies coordinated from project inception, specialized therapeutic area knowledge across 1,000+ completed programs, and proven regulatory pathways boasting a 96% approval rate.
Veranex's solution for the medical technology industry embeds reimbursement strategists and human factors engineers alongside designers and clinical researchers from the outset.
Image Credit: Veranex
What Makes This Trend Stand Out
- Accelerated Development Timelines
- Speeding up development timescales by three to six months per phase presents a compelling opportunity to disrupt traditional medical device timelines.
- Integrated Evidence Generation
- Coordinating evidence generation from the project's start to finish offers a streamlined approach to supporting regulatory submissions and market access applications.
- Reimbursement-integrated Design
- Incorporating reimbursement strategists early in the product development phase can transform market penetration strategies through better alignment with payers.
Sectors Adopting This
- Medical Technology
- Blending comprehensive CRO capabilities with lifecycle development expertise in medical technology projects innovates the pathways for medical breakthroughs.
- Healthcare Contract Research
- The emergence of iCROs represents a pivotal shift in healthcare CRO models, merging traditional and advanced research needs into a single entity.
- Regulatory Affairs
- High approval success rates via proven pathways highlight potential disruptions in the regulatory landscape for medical device approval processes.
